Gilead scores new FDA approval for drug obtained in billion-dollar purchase
Gilead Sciences has got a green light from the US Food and Drug Administration to use the drug Trodelvy for treating metastatic urothelial cancer. This is the second approval in a short time, as Trodelvy was recently approved for treating breast cancer.
BY ALBERT RØNNING ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
US company Gilead Sciences is still profiting off the fact that it purchased biotech company Immunomedics for USD 21bn last year, and through this deal, it acquired the drug Trodelvy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk and Gilead expand partnership
For subscribers
